title: First-Line Systemic Therapy for Non-Small Cell Lung Cancer.
abstract: Major advances in the treatment of metastatic non-small cell lung cancer have led to significant incremental improvements in patient outcomes. Platinum-based combination therapy remains the cornerstone of first-line therapy. The addition of biologic agents, such as bevacizumab or necitumumab, in selected populations has shown benefit over chemotherapy alone. The advent of maintenance therapy has also improved overall survival outcomes in selected populations of patients. Ongoing studies will further refine optimal treatment in the first-line setting and further advance first-line treatment options.
authors.affiliation: Department of Thoracic Oncology, Massachusetts General Hospital, 32 Fruit Street, Yawkey 7B, Boston, MA 02114, USA. Electronic address: rheist@partners.org.
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Heist
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D017671:Platinum Compounds / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D017671:Platinum Compounds; D061026:Programmed Cell Death 1 Receptor; C527969:necitumumab; D000068258:Bevacizumab
keywords: First-line; Non–small cell lung cancer; Systemic therapy